R-Tetrahydropapaverine N-acetyl-L-leucinate Pharmacy Grade

Tianjin Zhongrui Pharmaceutical co., Ltd. is a professional productive enterprise which dedicates to manufacture pharmaceutical ingredients and intermediates, and established in 2004 with total registered capital of CNY 26 million. The legal representative is Liu Changsuo and chief founders are natural persons from Beijing.  Company’s main products include Niacin, Niacinamide , Inositol Nicotinate, Terazosin Hcl, Amifostine, Strontium Renalate, Cisatracurium Besilate, Fasudil Hcl, Clopidogrel hydrogen sulfate, Dopamine Hcl, Febuxostat, etc.

Tianjin Zhongrui serves as an integrated pharmaceutical manufacturer, owning advanced production equipments, "GMP" workshops, and various sophisticated testing instruments. Most company leadership team members are professional and technical with rich experience in pharmaceutical, gaining college degree or above education. The site covers a total area of 21000㎡, of which production workshops 1656 ㎡, QC laboratory 360㎡. Production lines of all raw materials are equipped with special equipments and independent air conditioning system. Our quality control capability is qualified to the production scale. All products pass the GMP certification. Our facility conditions conform to the requirements of the technology, production safety, environmental protection. Internal research institute is equipped with advanced R&D equipments and pilot plant.

Tianijn Zhongrui relies on strong technical force, high-quality work team, perfect quality assurance system to build ourselves as a high-tech enterprise. Therefor the company has achieved rapidly development.
In 2009, Tianjin Zhongrui was identified as high-tech enterprises, and passed the reexamination in 2012. New production technology of Nicotinamide was incorporated into science and technology innovation projects of Tianjin Science and Technology Commission. Strontium Ranelate gets supported by “technology personnel service enterprise action” project of Ministry of Science. The company spent more than CNY3 million on R&D in 2012.
In 2009, in order to introduce the advanced production technology of new drugs and pursue the better development, Tianjin Zhongrui cooperated with a technology-based private institute from Beijing, which is specialized in new drug research and development. This institute invested six new drug’s research achievements and CNY6 million to Tianjin Zhongrui, which injected a huge fresh vitality of science and technology.